Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel–Lindau syndrome

[1]  Laura E. Herring,et al.  Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. , 2020, Molecular cell.

[2]  Laura E. Herring,et al.  TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss. , 2019, Cancer discovery.

[3]  C. Larsson,et al.  EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance , 2019, Proceedings of the National Academy of Sciences.

[4]  C. Fan,et al.  VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma , 2018, Science.

[5]  P. Cramer,et al.  Structural Basis of Mitochondrial Transcription Initiation , 2017, Cell.

[6]  O. Surova,et al.  Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA , 2017, Genes & development.

[7]  Matthew G. Vander Heiden,et al.  Understanding the Intersections between Metabolism and Cancer Biology , 2017, Cell.

[8]  W. Kaelin.  The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. , 2017, Transactions of the American Clinical and Climatological Association.

[9]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[10]  J. Cheng,et al.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner , 2016, Science.

[11]  F. Gage,et al.  Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation , 2016, eLife.

[12]  A. von Kriegsheim,et al.  Substrate-Trapped Interactors of PHD3 and FIH Cluster in Distinct Signaling Pathways , 2016, Cell reports.

[13]  U. Hellman,et al.  The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. , 2016, Developmental cell.

[14]  D. Figarella-Branger,et al.  Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas , 2016, Journal of Neuro-Oncology.

[15]  Y. Xiong,et al.  WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. , 2015, Molecular cell.

[16]  D. Lindgren,et al.  Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate , 2015, Cell Death and Disease.

[17]  S. Richard,et al.  Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. , 2014, Cancer research.

[18]  Jenny Welander,et al.  Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  S. Srikantan,et al.  In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. , 2013, Endocrine-related cancer.

[20]  D. Temiakov,et al.  Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease. , 2013, Molecular cell.

[21]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[22]  W. Harris,et al.  Metabolic differentiation in the embryonic retina , 2012, Nature Cell Biology.

[23]  J. Hornick,et al.  Succinate Dehydrogenase-deficient Tumors: Diagnostic Advances and Clinical Implications , 2012, Advances in anatomic pathology.

[24]  D. Gale,et al.  Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. , 2011, Blood.

[25]  Martijn A. Huynen,et al.  TEFM (c17orf42) is necessary for transcription of human mtDNA , 2011, Nucleic acids research.

[26]  Yuichi Matsushima,et al.  Mitochondrial Lon protease regulates mitochondrial DNA copy number and transcription by selective degradation of mitochondrial transcription factor A (TFAM) , 2010, Proceedings of the National Academy of Sciences.

[27]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[28]  Robert S. Freeman,et al.  Oxygen-Regulated β2-Adrenergic Receptor Hydroxylation by EGLN3 and Ubiquitylation by pVHL , 2009, Science Signaling.

[29]  W. Kaelin.  The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[30]  Christoph Handschin,et al.  The role of exercise and PGC1α in inflammation and chronic disease , 2008, Nature.

[31]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[32]  M. Meyerson,et al.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.

[33]  S. Signoretti,et al.  VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.

[34]  A. Pause,et al.  Collagen matrix assembly is driven by the interaction of von Hippel–Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 , 2008, Oncogene.

[35]  M. McMullin,et al.  A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. , 2008, The New England journal of medicine.

[36]  W. Rathmell,et al.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. , 2007, The Journal of clinical investigation.

[37]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[38]  P. Ratcliffe,et al.  Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor* , 2007, Journal of Biological Chemistry.

[39]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[40]  Huiyun Liang,et al.  PGC-1alpha: a key regulator of energy metabolism. , 2006, Advances in physiology education.

[41]  W. Kaelin,et al.  Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.

[42]  P. Choyke,et al.  Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. , 2004, Blood.

[43]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[44]  William Kim,et al.  The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. , 2003, Current opinion in genetics & development.

[45]  David Mole,et al.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia , 2002, Nature Genetics.

[46]  P. Ratcliffe,et al.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.

[47]  M. Ivan,et al.  von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.

[48]  K. Nagashima,et al.  The von Hippel-Lindau tumor suppressor targets to mitochondria. , 2000, Cancer research.

[49]  T. Shuin,et al.  Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. , 1999, Biochemical and biophysical research communications.

[50]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[51]  D. Louis,et al.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.

[52]  H. Brauch,et al.  Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. , 1997, The Journal of clinical endocrinology and metabolism.

[53]  LA Greene,et al.  Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium , 1978, The Journal of cell biology.

[54]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.